Introduction {#s1}
============

Oncology practice guidelines teach that neither cytotoxic therapy nor large-molecule target-specific therapies are routinely useful in treating cerebral metastases \[[@R01], [@R02]\] unless these arise from exquisitely chemosensitive primary tumors such as lymphomas or germ-cell neoplasms \[[@R03]\]. To address this unmet need, cerebral metastasectomy and/or sterotactic radiotherapy have become standards of care for most solid tumor patients with intracranial and limited extracranial metastatic disease \[[@R04]\], reflecting perceptions of a blood-brain barrier (BBB) that hinders transmembrane passage of drug molecules larger than 400 Da \[[@R05]\].

In recent years this orthodoxy has been challenged on empirical and theoretical grounds \[[@R06]\], with one objection being that the BBB is disrupted by intracerebral deposits larger than 1 cm \[[@R07]\]. HER2-overexpressing breast cancers are relevant to this debate, given that they recur preferentially within the brain \[[@R08]\], presumably reflecting the rich supply of HER-stimulatory heregulin ligands (neuregulins) \[[@R9]\] within the metastatic 'soil' of the central nervous system \[[@R10]\]. Relevant to this debate, we report here the history of a 50-year-old woman who presented with aggressive metastatic HER2+ breast cancer that required immediate upfront systemic therapy.

Case Report {#s2}
===========

A 50-year-old female presented in July 2012 after noticing thickening in the lateral aspect of the right breast. Core biopsy confirmed a 20 mm hormone receptor-negative grade 2 invasive ductal carcinoma with high levels of HER2 by both immunohistochemistry and in-situ hybridization. The patient reported no symptoms of metastatic disease, including no headaches or focal symptoms. Examination demonstrated a palpable breast mass with matted axillary lymph nodes, and normal neurological status. PET/CT scan demonstrated FDG-avid metastases in the right breast, right axillary lymph nodes, and multiple bilateral pulmonary nodules; in addition, however, a large photopenic and hypoattenuating area was detected in the right frontal lobe. CT-guided biopsy of a pulmonary nodule confirmed adenocarcinoma. Brain MRI confirmed two frontal lobe lesions ([Fig. 1](#F1){ref-type="fig"}) (upper panels), the largest 28 mm, with extensive surrounding oedema. Gamma-knife surgery was deemed unfeasible due, but this was deemed unfeasible due to the size of the two lesions. Treatment was commenced using dexamethasone for cerebral oedema and 3-weekly standard chemotherapy using docetaxel/carboplatin plus trastuzumab (Herceptin™; DCH) with pegfilgrastim support. Repeat CT scan prior to the second cycle of DCH revealed a partial response, while a repeat MRI after five cycles showed a complete response ([Fig. 1](#F1){ref-type="fig"}). There was also a clinical remission of the breast mass, a radiologic complete remission of the axillary adenopathy, plus near-complete remission of the pulmonary metastases. The patient continues on trastuzumab.

![MRI appearances of brain metastases before (pre-TCH, above) and after drug treatment (post-TCH, below). Fluid attenuated inversion recovery (FLAIR) images are shown at left, and T1-weighted images at right.](wjon-04-122-g001){#F1}

Discussion {#s3}
==========

Complete responses of brain metastases to systemic therapies have been reported for kinase inhibitor therapy of lung cancer \[[@R11]\]; for cytotoxic chemotherapy of germ-cell tumors \[[@R12]\]; and in breast cancer, for hormonal therapy \[[@R13]\], concurrent chemoradiation plus lapatinib \[[@R14]\], and (for small brain secondaries only) oral capecitabine \[[@R15]\]. In addition, responses of leptomeningeal breast cancer have been reported using intrathecal trastuzumab \[[@R16]\]. Partial responses of intracerebral metastases are reported in pre-treated patients receiving tamoxifen \[[@R17]\], trastuzumab-radiation \[[@R18]\], trastuzumab-cytotoxic combinations \[[@R19]\], and capecitabine-lapatinib \[[@R20]\]. These testimonials to drug efficacy suggest that the traditional notion of the blood-brain barrier may be declining in relevance to the management of brain metastasis.

Trastuzumab reportedly exhibits poor penetration into the brain \[[@R21]\], and is widely believed to be ineffective in controlling brain metastases in breast cancer patients \[[@R22]\]. Despite this, trastuzumab induces radiosensitization in the context of cerebral metastases \[[@R23]\], and patients with HER2-positive brain metastases who continue trastuzumab experience longer survival \[[@R24], [@R25]\]. In contrast, the anticipated efficacy of the small-molecule HER2 kinase inhibitor lapatinib as single-agent therapy for brain metastases has proven to be marginal \[[@R26]\]. Indeed, based on published reports, we can infer no inverse relationship between drug molecular weight ([Table 1](#T1){ref-type="table"}) and clinical efficacy of brain metastasis therapy in breast cancer patients.

###### Molecular Weights of Relevant Oncology Drugs

  Drug                Reported efficacy in solid tumour cerebral metastases   MWt (Da)
  ------------------- ------------------------------------------------------- ----------
  Capecitabine        \+                                                      360
  Carboplatin         \+                                                      371
  Tamoxifen           \+                                                      372
  Megestrol acetate   \+                                                      384
  Gefitinib           \+                                                      447
  Doxorubicin         \-                                                      580
  Etoposide           \+                                                      587
  Docetaxel           \-                                                      808
  Lapatinib           \+                                                      944
  Trastuzumab         \+                                                      148,000

The putative blood-brain barrier cut-off is 400 Da. MWt: molecular weight; Da: daltons.

In summary, just as there is growing enthusiasm for first-line use of HER2 inhibitors in lieu of chemotherapy for early breast cancer \[[@R27]\], so does the present case suggest that trastuzumab-based chemotherapy could come to displace surgery and/or radiation therapy in selected cases of HER2-positive bulky brain metastases. Accordingly, in this palliative context, we submit that chemonaive HER2-positive intracerebral disease should now join lymphomas and germ-cell tumors in the category of "highly chemosensitive tumors" \[[@R03]\].
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